WAYNE, N.J. and CHICAGO, Nov. 30 (HSMN NewsFeed) — Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an in…
Biopharmaceuticals, Devices, Radiology, Neurology
Bayer HealthCare, florbetaben, PET imaging, amyloid, Alzheimer’s

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer’s Disease”
Leave a Comment